Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
IPO Year:
Exchange: NASDAQ
Website: kaziatherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/6/2025 | $3.00 | Buy | Maxim Group |
| 10/14/2021 | $18.00 | Buy | Maxim Group |
Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY, March 31, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD $1 million. In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantrixil from Kazia Therapeutics. Having decided not to pursue development of Cantrixil in ovarian cancer, as originally anticipated under the license, Vivesto is currently exploring Cantri
SYDNEY, Feb. 20, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced a research grant awarded from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson's disease (PD). The grant will fund collaborative preclinical studies at Professor Ronit Sharonʼs lab (Hebrew University) aimed at establishing an operat
SYDNEY, Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer. The ABC-Pax (Advanced Breast Cancer – Paxalisib) study is the first known trial conducted to assess the safety and ef
SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previously announced registered direct offering with existing fundamental healthcare investor, Alumni Capital LP, of 1,333,333 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing 100 ordinary shares of the Company, at a purchase price of $1.50 per ADS (or ADS equivalent in lieu thereof) and concurrent private placement of unregistered warrants to purchase up to an aggregate of 1,333,333 ADSs. The warrants will have an exercise price of $1.50 p
SYDNEY, Jan. 10, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing 100 ordinary shares of the Company, at a purchase price of $1.50 per ADS (or ADS equivalent in lieu thereof), in a registered direct offering. The Company has also agreed to issue, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 1,333,333 ADSs. The warrants will hav
SYDNEY, Dec. 31, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food and Drug Administration (FDA). In July 2024, the Company reported topline results from the GBM-AGILE study in which newly diagnosed unmethylated (NDU) patients with glioblastoma treated with paxalisib showed a clinically meaningful improvement in a prespecified secondary analysis for overall survival (
SYDNEY, Dec. 11, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast Cancer Symposium highlighting the activity the Company's lead product candidate, paxalisib, for the potential treatment of immunotherapy-resistant triple negative breast cancer (TNBC) and HER2 positive metastatic breast cancer with active brain metastases. "Immunotherapy-resistant triple negative breast cancer represents one of the most difficult-to-treat areas of breast cancer,
Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming medical meetings SYDNEY, Nov. 4, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, announced that the U.S. Food and Drug Administration (FDA) has granted a Type C meeting with the Company in December 2024 to discuss the potential pathways to registration of Kazia's blood brain barrier penetrant PI3K/mTOR inhibitor, paxalisib, for the treatment of patients with newly diagnosed GBM. In July 2024, the Company announced results from the Ph
Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR) Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably to historical response rates for whole brain radiation therapy alone SYDNEY, Oct. 2, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation
SYDNEY, Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington. Dr. John Friend, CEO Kazia Therapeutics presented preliminary data from a Phase 1 first-in-
SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer
SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022. Kazia CEO, Dr. James Garner, commented, "
SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States. Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clin
Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00
Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00
SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
6-K - KAZIA THERAPEUTICS LTD (0001075880) (Filer)
424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)